What is secretory carcinoma of the salivary gland?
Secretory carcinoma is an uncommon, usually low-grade cancer of the salivary glands. It most often starts in the parotid gland, in front of the ear, but it can also arise in the small salivary glands of the lips, cheeks and palate, and in the submandibular gland under the jaw.
The tumour was first recognised as a separate disease in 2010. Before then, it was usually diagnosed as acinic cell carcinoma or as an unclassified adenocarcinoma. Because it looks very similar to secretory carcinoma of the breast, it was at first named mammary analogue secretory carcinoma (MASC) (Skálová et al., 2010).
The defining feature is a gene fusion, most often between the ETV6 and NTRK3 genes. This fusion produces an abnormal protein that drives tumour growth. It matters for patients because TRK inhibitor medicines, such as larotrectinib and entrectinib, can block it and shrink advanced tumours (Bebb et al., 2021).
Secretory carcinoma can occur at almost any age, including in children and teenagers. Most people are cured by surgery, but a minority have tumours that spread to lymph nodes or behave more aggressively.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Usually low-grade salivary gland carcinoma |
| How common | Uncommon; a few per cent of salivary gland cancers |
| Typical age | Wide range, from childhood to old age; average mid-40s |
| Sex | Roughly equal (about 52% male in a large review) |
| Main site | Parotid gland in most; also lips, cheek, palate and submandibular gland |
| Key gene change | ETV6::NTRK3 fusion in most; ETV6::RET and other fusions in some |
| Main treatment | Surgical removal; radiotherapy in selected cases |
| Advanced disease | TRK inhibitors (larotrectinib, entrectinib, repotrectinib) or RET inhibitors |
| Outlook | Generally good; worse with high-grade transformation or spread |
2. Causes and risk factors
The cause of secretory carcinoma is not known. It does not seem to be related to smoking, alcohol or viral infections.
The gene fusion
| Gene fusion | Notes |
|---|---|
| ETV6::NTRK3 | The classic fusion, found in most tumours; the same fusion occurs in breast secretory carcinoma and some childhood tumours |
| ETV6::RET | Found in a minority; may respond to RET-blocking drugs |
| ETV6::MET, VIM::RET and others | Rare alternative partners |
A gene fusion happens when two separate genes break and join together inside a cell. The new hybrid gene sends constant “grow” signals. These fusions are acquired in the tumour and are not inherited.
| Risk factor | Notes |
|---|---|
| Previous radiation to the head and neck | A general risk factor for salivary gland cancers |
| Age and sex | No strong pattern; children and adults are both affected |
3. How does it look
To the patient
Secretory carcinoma usually appears as a slow-growing, painless lump.
| Feature | Description |
|---|---|
| Feel | Firm, rubbery, sometimes partly soft or cystic |
| Size | Often 1-3 cm |
| Growth | Slow, sometimes over years |
| Skin or lining | Usually normal |
| Mobility | Often moves under the finger |
On scans
On ultrasound or MRI, the tumour usually looks well defined, often with cystic (fluid-filled) areas. It can easily be mistaken for a benign tumour such as a pleomorphic adenoma or Warthin tumour.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Uniform cells with pale pink, bubbly cytoplasm and round nuclei |
| Patterns | Microcystic, tubular, follicular, papillary-cystic and solid |
| Secretions | Pink, bubbly secretory material inside small spaces |
| Stains | S100, mammaglobin and SOX10 positive; DOG1 usually negative |
| TRK stain | Pan-TRK immunohistochemistry often positive |
| Molecular test | FISH or sequencing confirms the ETV6 fusion |
| High-grade transformation | Areas of very abnormal cells and necrosis in a small number |
How it differs from acinic cell carcinoma
| Feature | Secretory carcinoma | Acinic cell carcinoma |
|---|---|---|
| Granules in cells | Absent | Present (zymogen granules) |
| DOG1 stain | Usually negative | Positive |
| Mammaglobin stain | Positive | Usually negative |
| Gene change | ETV6 fusion | NR4A3 activation |
| Targeted drugs | TRK or RET inhibitors | None routinely available |
4. Symptoms
Common symptoms
- A painless lump in front of or below the ear
- A small lump on the lip, cheek or roof of the mouth
- A lump under the jaw
- Slow growth over months or years
Signs that need prompt attention
| Sign | Possible meaning |
|---|---|
| Pain | Growth into surrounding tissue or nerves |
| Facial weakness | Involvement of the facial nerve |
| Rapid growth | Possible high-grade transformation |
| Lumps in the neck | Spread to lymph nodes |
| Fixed, hard lump | Invasion of nearby tissue |
Symptoms of spread
Spread beyond the neck is uncommon. When it happens, it may affect the lungs (cough, breathlessness) or bones (bone pain).
When to seek medical advice
See a doctor or dentist about any lump in the face, mouth or neck that lasts more than 3 weeks. Seek prompt review if it is painful, growing quickly, or linked with facial weakness or swollen neck glands.
5. Diagnosis
| Test | Purpose |
|---|---|
| Examination | Assesses the lump, facial nerve and neck nodes |
| Ultrasound | First test for salivary lumps; guides sampling |
| Fine needle aspiration (FNA) or core biopsy | Takes cells or tissue for diagnosis |
| MRI | Shows the extent of the tumour and its relation to the facial nerve |
| CT or PET-CT | For larger tumours or suspected spread |
| Immunohistochemistry | S100, mammaglobin, SOX10, DOG1 and pan-TRK |
| Molecular testing | Confirms ETV6::NTRK3 or another fusion |
Why the fusion test matters
Testing for the gene fusion confirms the diagnosis. It also identifies who could benefit from targeted medicines if the cancer ever comes back or spreads. Experts recommend NTRK fusion testing for salivary tumours with features of secretory carcinoma (Bebb et al., 2021).
Staging
Secretory carcinoma is staged in the same way as other major salivary gland cancers, using the TNM system:
| Stage group | Meaning in simple terms |
|---|---|
| Stage I-II | Tumour confined to the gland, up to 4 cm, no lymph node spread |
| Stage III | Larger tumour, growth just beyond the gland, or a single small lymph node |
| Stage IV | Invasion of skin, bone, nerves or major vessels, more extensive node spread, or distant spread |
Most secretory carcinomas are found at stage I or II.
6. Treatment
Treatment is planned by a head and neck cancer team.
Surgery
| Operation | Notes |
|---|---|
| Superficial or total parotidectomy | For parotid tumours; the facial nerve is preserved whenever possible |
| Submandibular gland excision | For tumours under the jaw |
| Wide local excision | For tumours in the lip, cheek or palate |
| Neck dissection | When lymph nodes are involved, or for high-grade tumours |
Radiotherapy
Radiotherapy after surgery is not usually needed for small, completely removed, low-grade tumours. It may be recommended for:
- Close or positive margins
- High-grade transformation
- Large tumours or spread beyond the gland
- Lymph node involvement or nerve invasion
Targeted medicines
| Medicine | Target | Notes |
|---|---|---|
| Larotrectinib | TRK (NTRK fusions) | Tablet or liquid; approved for NTRK fusion-positive cancers in adults and children |
| Entrectinib | TRK, ROS1 and ALK | Capsule; also reaches the brain well |
| Repotrectinib | TRK and ROS1 | Newer drug, also active after resistance to earlier TRK inhibitors |
| Selpercatinib or pralsetinib | RET | For tumours with RET fusions |
These medicines are used for advanced, recurrent or inoperable disease. Responses can be rapid and long-lasting, and some people with advanced disease have lived for years on treatment (Ernst et al., 2022).
Secretory carcinoma in children and young people
Salivary gland cancers are rare in childhood, but secretory carcinoma is one of the types seen in children and teenagers. It usually appears as a painless lump in the parotid area or in the mouth.
Treatment follows the same principles as in adults, with careful surgery that protects the facial nerve. Radiotherapy is used sparingly in children because of its effects on growth of the face and jaw. If treatment with medicines is ever needed, larotrectinib is available as a liquid and is approved for children with NTRK fusion-positive cancers.
How TRK inhibitors work
The NTRK3 gene normally makes a receptor that helps nerve cells develop. When it is fused to ETV6, the receptor is switched on permanently. TRK inhibitors fit into the active site of this receptor and block its signals, which stops the tumour cells from growing. These medicines are called tumour-agnostic treatments, because they are approved for any cancer that carries an NTRK fusion, wherever it starts in the body.
Side effects
| Treatment | Possible side effects |
|---|---|
| Parotid surgery | Temporary facial weakness, numb ear lobe, sweating when eating (Frey syndrome) |
| Radiotherapy | Dry mouth, sore skin, taste changes, jaw stiffness |
| TRK inhibitors | Dizziness, weight gain, tiredness, muscle aches, raised liver enzymes, pain when stopping |
| RET inhibitors | High blood pressure, dry mouth, liver changes, swelling |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Parotidectomy | General anaesthetic; usually 1-2 nights in hospital |
| Recovery | Normal activities within 2-3 weeks for most people |
| Radiotherapy, if needed | Weekday sessions for about 6 weeks |
| Targeted tablets | Taken at home, with regular clinic visits, blood tests and scans |
7. Outlook (prognosis)
| Situation | Usual outlook |
|---|---|
| Low-grade tumour, completely removed | Excellent; most people are cured |
| Lymph node spread | About 15% of patients; usually still controlled with surgery and radiotherapy |
| High-grade transformation | More aggressive; higher risk of recurrence and spread |
| Advanced disease with a targetable fusion | Often well controlled for long periods with targeted medicines |
A worldwide review of 674 published patients found that most were diagnosed at an early stage. About 15% had spread to neck lymph nodes, about 8% developed distant spread, and the tumour came back in roughly 1 in 5 (Yosefof et al., 2024). About 1 in 6 patients in these reports died of the disease. Published case reports may over-represent unusual or severe cases, and these figures come mostly from the years before targeted medicines were widely available.
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic visits every 3-6 months at first | Examine the surgical area, facial nerve and neck |
| Ultrasound or MRI | Detect recurrence |
| Chest imaging | For high-grade or node-positive tumours |
| Long-term follow-up | Usually at least 5-10 years |
9. Living with secretory carcinoma
- Check the area around your scar and neck for new lumps once a month, and report anything new
- Look after your mouth and teeth, especially after radiotherapy
- Ask about Frey syndrome treatment if you sweat on your cheek when eating
- Keep a record of your tumour’s gene fusion result, which may matter for future treatment
- Ask about clinical trials if the cancer returns
- Tell any new doctor that your tumour carries a gene fusion, as this can open up specific treatment options
- Plan a gradual return to work or school after surgery, which most people manage within a few weeks
- Seek support from head and neck cancer charities
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is it related to breast cancer? | No. It only looks like a type of breast cancer under the microscope and shares the same gene fusion |
| Is it inherited? | No |
| Can children get it? | Yes, it is one of the salivary cancers seen in young people |
| Will I need chemotherapy? | Rarely; targeted tablets are preferred for advanced disease |
| What is a TRK inhibitor? | A medicine that blocks the abnormal protein made by the NTRK fusion |
| Does a gene fusion mean my family is at risk? | No. The fusion is found only in the tumour and is not passed on |
| Was my earlier diagnosis wrong? | Before 2010 many of these tumours were labelled acinic cell carcinoma, because the newer tests did not yet exist |
11. Questions to ask your care team
- Has my tumour been tested for an ETV6 or NTRK fusion?
- Is it low grade or high grade?
- Were the margins clear?
- Do I need radiotherapy or a neck dissection?
- Would a targeted medicine be an option if it came back?
- How long will my follow-up last?
Resources
- Bebb, D.G. et al. (2021) ‘Canadian consensus for biomarker testing and treatment of TRK fusion cancer in adults’, Current Oncology, 28(1), pp. 523-548.
- Ernst, M.S. et al. (2022) ‘TRK inhibition with entrectinib in metastatic salivary secretory carcinoma (SC): a case report’, Current Oncology, 29(6), pp. 3933-3939.
- Skálová, A. et al. (2010) ‘Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity’, American Journal of Surgical Pathology, 34(5), pp. 599-608.
- Yosefof, E. et al. (2024) ‘Salivary gland secretory carcinoma; review of 13 years world-wide experience and meta-analysis’, Laryngoscope, 134(4), pp. 1716-1724.
- National Cancer Institute (2026) Salivary Gland Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/salivary-gland-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.